Voclosporin: Physiology and What Research Reports

What Voclosporin Is

Voclosporin is a cyclic undecapeptide — an eleven-amino-acid ring molecule — belonging to the calcineurin inhibitor class, and it is one of the reasons the term appears in peptide reading lists despite being a small-molecule-style prescription drug. A clinical pharmacology review described voclosporin as a structural analogue of cyclosporine A that differs by a modification at the amino acid-1 residue, a change the authors linked to altered calcineurin-binding potency and faster metabolism (PMID 37133755). A first-approval summary reported that voclosporin was approved in the USA in January 2021 for adults with active lupus nephritis, used in combination with background immunosuppressive therapy (PMID 33788181).

This page is for educational purposes only and is not medical advice; consult a licensed physician for any question about diagnosis, treatment or medication.

Where It Acts in the Body

Calcineurin is a calcium- and calmodulin-dependent phosphatase found in T lymphocytes and in kidney cells. When a T-cell receptor is engaged, calcineurin dephosphorylates nuclear factor of activated T cells (NFAT), allowing it to enter the nucleus and switch on cytokine genes including interleukin-2. Reviews of voclosporin in lupus nephritis described the drug as binding cyclophilin A and blocking that calcineurin–NFAT step, reducing T-cell cytokine output (PMID 35763288).

The same reviews described a second, kidney-local action: calcineurin inhibition has been proposed to stabilise the podocyte cytoskeleton, which is relevant to protein leakage across the glomerular filter (PMID 35763288). An earlier evaluation of voclosporin for lupus nephritis discussed this combination of immune and structural effects as the rationale for testing the drug in glomerular disease (PMID 30207816).

Because calcineurin also operates in renal tubules and vascular smooth muscle, class effects extend beyond immunity. A 2024 nephrology study compared tacrolimus and voclosporin with respect to kidney electrolyte handling and blood pressure, examining how the two calcineurin inhibitors differ in these non-immune actions (PMID 38777623).

How It Is Measured and Studied

Research on voclosporin has relied on several categories of measurement:

• Pharmacokinetics and pharmacodynamics. A pharmacokinetics review reported that voclosporin showed a comparatively predictable concentration–effect relationship and limited accumulation of metabolites, which the authors related to the absence of routine therapeutic drug-level monitoring in its trial programme (PMID 37133755).
• Renal response endpoints. The phase 3 lupus nephritis trial defined complete renal response using urine protein-to-creatinine ratio together with stable estimated glomerular filtration rate and limits on rescue steroids (PMID 33971155).
• Kidney biopsy. A 2025 analysis examined renal histology in patients with active lupus nephritis who underwent repeat renal biopsies after long-term voclosporin treatment (PMID 40317902).

What the Clinical Literature Reports

The dose-ranging phase 2 study tested voclosporin 23.7 mg and 39.5 mg twice daily against placebo on a background of mycophenolate mofetil and reported a higher rate of complete remission at 24 weeks with the lower dose than with placebo (PMID 30420324). The phase 3 AURORA 1 trial randomised adults with lupus nephritis to voclosporin 23.7 mg twice daily or placebo, each with mycophenolate mofetil and rapidly tapered low-dose glucocorticoids, and researchers reported complete renal response at 52 weeks in 41% of the voclosporin group versus 23% of the placebo group (PMID 33971155).

The AURORA 2 continuation study followed participants for a further period of treatment and reported that renal response measures and estimated glomerular filtration rate remained stable over the extended treatment period, with no new safety signals identified (PMID 37466424). A separate analysis focused on proliferative lupus nephritis with high baseline proteinuria and reported renal response outcomes in that subgroup (PMID 38110196).

A propensity-matched comparison set the voclosporin-based triple regimen against a high-dose glucocorticoid-based regimen drawn from an earlier lupus nephritis trial, and the authors reported on renal response alongside differences in cumulative steroid exposure (PMID 39521453).

Voclosporin Adverse Events: What Studies Report

In AURORA 1, researchers reported that serious adverse events occurred at broadly similar frequency in the voclosporin and placebo groups when both were given with mycophenolate mofetil and low-dose glucocorticoids (PMID 33971155). The phase 2 dose-ranging study reported more deaths among voclosporin-treated participants than among those receiving placebo, a finding the investigators discussed in the context of the study population and settings (PMID 30420324).

The AURORA 2 continuation reported that longer-term treatment was not associated with new safety signals beyond those already described in the 52-week trial (PMID 37466424). Class-level concerns for calcineurin inhibitors — including effects on kidney function, blood pressure and electrolytes — were examined directly in a comparison of tacrolimus and voclosporin on renal electrolyte handling and blood pressure (PMID 38777623). A review of voclosporin's pharmacology discussed how its metabolism and exposure profile relate to these tolerability considerations (PMID 37133755).

Why the Term Appears in Peptide Reading

Voclosporin is frequently encountered by readers researching peptide therapeutics because it is a peptide by chemistry — a cyclic, largely N-methylated ring that resists ordinary peptidase breakdown and survives oral administration, unlike most linear research peptides. Reviews of its development described it as a modified cyclosporine designed to improve potency and pharmacokinetic predictability (PMID 30207816). Its literature also crosses into dermatology: a review of systemic calcineurin inhibitors catalogued off-label dermatologic uses reported for tacrolimus and voclosporin (PMID 37307993).

Limits of the Evidence

Most of the human data sit within a single disease programme. The phase 3 evidence base was built in adults with active lupus nephritis receiving mycophenolate mofetil and glucocorticoids, so the reported outcomes describe a combination regimen rather than voclosporin alone (PMID 33971155). Comparisons with older regimens have come from propensity-matched analyses rather than head-to-head randomisation, which the authors acknowledged as a methodological constraint (PMID 39521453). Voclosporin is a prescription medicine; the literature summarised here describes supervised clinical research, not self-directed use.

References

• Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial (Lancet, 2021)
• Safety and Efficacy of Long-Term Voclosporin Treatment for Lupus Nephritis in the Phase 3 AURORA 2 Clinical Trial (Arthritis & Rheumatology, 2024)
• Voclosporin: First Approval (Drugs, 2021)
• Clinical Pharmacokinetics and Pharmacodynamics of Voclosporin (Clinical Pharmacokinetics, 2023)
• Comparison of a voclosporin-based triple immunosuppressive therapy to high-dose glucocorticoid-based immunosuppressive therapy: a propensity analysis of the AURA-LV and AURORA 1 studies and ALMS (Lupus Science & Medicine, 2024)
• Systemic calcineurin inhibitors tacrolimus and voclosporin: A review of off-label dermatologic uses (Journal of the American Academy of Dermatology, 2024)
• Efficacy of Voclosporin in Proliferative Lupus Nephritis with High Levels of Proteinuria (CJASN, 2024)
• Calcineurin inhibitor effects on kidney electrolyte handling and blood pressure: tacrolimus versus voclosporin (Nephrology Dialysis Transplantation, 2024)
• A randomized, controlled double-blind study comparing the efficacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis (Kidney International, 2019)
• An evaluation of voclosporin for the treatment of lupus nephritis (Expert Opinion on Pharmacotherapy, 2018)
• Voclosporin: a novel calcineurin inhibitor for the treatment of lupus nephritis (Expert Review of Clinical Pharmacology, 2022)
• Effect of Long-Term Voclosporin Treatment on Renal Histology in Patients With Active Lupus Nephritis With Repeat Renal Biopsies (Arthritis & Rheumatology, 2025)